Home › Therapeutic areas › Renal › Immunoglobulin A Nephropathy
Immunoglobulin A Nephropathy (8 companies)
Companies with an active program in Immunoglobulin A Nephropathy.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AKBA | Akebia Therapeutics | HematologyOphthalmology+2 Rare | 1 | Approved | $111M | 10 |
| CLYM | Climb Bio | HematologyImmunology+1 Rare | 1 | Phase 2 | $604M | 8 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 1 | Approved | $6.55B | 29 |
| JBIO | Jade Biosciences | ImmunologyRenal Rare | 1 | Phase 2 | $958M | 4 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 1 | Phase 3 | $719M | 9 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 1 | Phase 2 | $5.4M | 7 |
| TVTX | Travere Therapeutics | MetabolicRenal Rare | 1 | Approved | $4.76B | 7 |
| VERA | Vera Therapeutics | Infectious DiseaseRenal Rare | 1 | Approved | $2.15B | 6 |
No companies match.